---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-004156"
form_type: "8-K"
ticker: "OKUR"
cik: "0001637715"
company_name: "OnKure Therapeutics, Inc."
filed_at: "2022-03-23T23:59:59+00:00"
generated_at: "2026-06-26T19:43:20.238860+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Reneo Pharma reports Q4 net loss $10.6M; cash $147.7M; no Phase 2 for McArdle

## Summary
- Net loss for Q4 2021 was $10.6M ($0.43 per share) vs $6.3M in Q4 2020; full year net loss $39.8M.
- Cash, cash equivalents and short-term investments at Dec 31, 2021: $147.7M, sufficient into 2024.
- STRIDE Phase 2b PMM study enrollment ongoing; data expected in 2023; LC-FAOD data in 2Q 2022.
- REN001 in McArdle disease: no drug-related SAEs; company will not pursue Phase 2 for McArdle.
- Appointed Ashley Hall as Chief Development Officer and Eric Dube to Board of Directors.

## SEC filing metadata
- accession: 0001558370-22-004156
- form_type: 8-K
- ticker: OKUR
- cik: 0001637715
- company_name: OnKure Therapeutics, Inc.
- filed_at: 2022-03-23T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1637715/000155837022004156/0001558370-22-004156-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1637715/000155837022004156/rphm-20220323x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-004156
- JSON: https://secwatch.observer/filing/0001558370-22-004156.json
- Plain text: https://secwatch.observer/filing/0001558370-22-004156.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.